Table I.
Patient Demographics and Baseline Disease Characteristics
| Lumiracoxib (n=9117) | NSAIDs (n=9127) | |
|---|---|---|
| Age, y | 63.5±8.37 | 63.4±8.35 |
| Female | 6963 (76.4) | 6970 (76.4) |
| BMI, kg/m2 | 29.6±5.70 | 29.5±5.64 |
| Race | ||
| Caucasian | 6892 (75.6) | 6846 (75.0) |
| Hispanic | 1476 (16.2) | 1514 (16.6) |
| African American | 187 (2.1) | 190 (2.1) |
| Other | 562 (6.2) | 577 (6.3) |
| Low‐dose aspirin use | 2167 (23.8) | 2159 (23.7) |
| At high CV riska or with a CCV history | 1141 (12.5) | 1066 (11.7) |
| Dyslipidemia at baseline | 1829 (20.1) | 1834 (20.1) |
| Hyperlipidemia at baseline | 509 (5.6) | 495 (5.4) |
| Diabetes at baseline | 744 (8.2) | 675 (7.4) |
| Normotensive and no hypertensive treatment | ||
| No. (%) | 4434 (48.6) | 4612 (50.5) |
| SBP | 128.0±14.7 | 128.1±14.6 |
| DBP | 78.2±8.5 | 77.9±8.4 |
| Normotensive and hypertensive treatment | ||
| No. (%) | 464 (5.1) | 454 (5.0) |
| SBP | 128.8±14.2 | 130.0±14.5 |
| DBP | 77.5±9.2 | 77.3±8.0 |
| Hypertensive and no hypertensive treatment | ||
| No. (%) | 343 (3.8) | 336 (3.7) |
| SBP | 137.9±15.2 | 138.2±16.4 |
| DBP | 83.6±8.5 | 82.8±9.7 |
| Hypertensive and hypertensive treatment | ||
| No. (%) | 3876 (42.5) | 3725 (40.8) |
| SBP | 137.4±15.3 | 138.1±15.9 |
| DBP | 81.8±8.7 | 82.0±9.1 |
| Concomitant antihypertensive medicationb | ||
| No. (%) | 4340 (47.6) | 4179 (45.8) |
| Monotherapyc | 2154 (23.6) | 2073 (22.7) |
| Combination therapyc | 2134 (23.4) | 2064 (22.6) |
| β‐Blocker, selective | 949 (10.4) | 893 (9.8) |
| β‐Blocker, nonselective | 201 (2.2) | 215 (2.4) |
| ACE inhibitor, plain | 1554 (17.0) | 1469 (16.1) |
| ACE inhibitor and diuretic | 231 (2.5) | 203 (2.2) |
| Angiotensin II receptor blocker, plain | 334 (3.7) | 347 (3.8) |
| Angiotensin II receptor blocker and diuretic | 167 (1.8) | 150 (1.6) |
| Dihydropyridine calcium channel blocker | 741 (8.1) | 712 (7.8) |
| Thiazide diuretic, plain | 459 (5.0) | 427 (4.7) |
| Sulfonamide diuretic, plain | 447 (4.9) | 423 (4.6) |
| Nitrates | 286 (3.1) | 244 (2.7) |
| Abbreviations: ACE, angiotensin converting enzyme; BMI, body mass index; CCV, cardiovascular and cerebrovascular; CV, cardiovascular; DBP, diastolic blood pressure; NSAIDs, nonsteroidal antiinflammatory drugs; SBP, systolic blood pressure. Values are mean ± SD or No. (%). aAs defined in the US National Institutes of Health National Heart, Lung, and Blood Institute Framingham Heart Study risk algorithm. bDrugs taken before randomization (not all antihypertensive classes are listed. The 5 most commonly used antihypertensive classes are listed along with some other classes and combinations of interest). cTreatment codes for antihypertensive treatment that did not make a clear distinction between monotherapy and combination therapy were not included. | ||